‘Super Herceptin’ Excels in HER2 Breast Cancer

Data from the phase 3 EMILIA trial shows progression-free survival benefit in metastatic HER2-positive breast cancer patients.

BY ELIZABETH WHITTINGTON
PUBLISHED: JUNE 07, 2012
The investigational breast cancer drug T-DM1 had a sputtering start when the Food and Drug Administration refused to grant it accelerated approval in 2010, even with promising phase 2 data. As the ASCO headliner this year, though, it appears new data from the large phase 3 trial, called EMILIA, will be enough to gain approval and make it available to metastatic HER2-positive breast cancer patients soon.T-DM1 is one of a reformulated class of drugs called antibody-drug conjugates. It fuses together the Herceptin antibody (trastuzumab) to a potent drug called emtansine, packing a powerful punch to cancers that are fueled by overexpression of the HER2 receptor—even in patients whose cancers have prog- ressed with Herceptin. Emtansine’s potency is at least 100 times more powerful than paclitaxel, and administration without severe side effects has been a challenge until now. Linking it to Herceptin, which delivers it directly to the cancer cell, reduces those side effects. 

In the EMILIA trial, researchers followed 978 women whose cancer had progressed on a taxane and Herceptin. The women were given either an infusion of T-DM1 three times a week or the standard treatment of Xeloda (capecitabine) and Tykerb (lapatinib). After two years, researchers found that women in the investigational arm lived longer without disease progression (9.6 months compared with 6.4 months with standard therapy) and had fewer treatment-related side effects. There also appears to be a survival advantage, but researchers are waiting for data to mature before they can confirm that T-DM1 prolongs life. At the two-year follow-up, 65.4 percent of patients on T-DM1 were alive compared with 47.5 percent on the standard treatment.

"I'd say close to 18 more out of 100 women were alive because they got one drug over another," says Kimberly L. Blackwell, MD, who presented the study at ASCO. "We've never seen that kind of absolute difference in overall survival for a drug that doesn't induce life-altering toxicities. We haven't even seen that amount of survival benefit in highly toxic treatments." 

Although the EMILIA trial tested T-DM1 alone, there are clinical trials combining T-DM1 with approved and investigational drugs, including pertuzumab, which was recently granted approval for metastatic breast cancer on June 8. Data from the EMILIA trial will be submitted to the FDA later this year for possible approval in metastatic, HER2-positive breast cancer.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
x
//For side ad protocol